Our results suggest that the BM CD8+ CTL subset in the studied AML cases represents a crucial component of the immune cell composition, showing significant associations with certain prognostic hematological and clinical parameters, as well as response to therapy. Here, CD8A is linked to acute myeloid leukemia.